TSE:4578Pharmaceuticals
Will Positive Phase 3 Results for Sibeprenlimab Shift Otsuka Holdings' (TSE:4578) Investment Narrative?
On November 9, 2025, Otsuka Pharmaceutical reported 12-month interim results from its Phase 3 VISIONARY trial of sibeprenlimab for IgA nephropathy at the American Society of Nephrology Kidney Week, with summary data published in The New England Journal of Medicine.
The interim analysis showed sibeprenlimab achieved a substantial reduction in proteinuria versus placebo, supporting Otsuka's recent U.S. FDA Priority Review and highlighting its innovative approach to tackling a rare kidney...